41498-10-6

Usage

Uses

Used in Pharmaceutical Industry:
4-[1,2,3]TRIAZOL-1-YL-BENZALDEHYDE is used as an intermediate in the synthesis of various pharmaceuticals due to its ability to react with other compounds to form new medicinal agents. Its presence in the molecular structure can contribute to the development of drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 4-[1,2,3]TRIAZOL-1-YL-BENZALDEHYDE serves as an intermediate for the production of agrochemicals, potentially enhancing crop protection and yield through the development of new pesticides and other agricultural chemicals.
Used in Organic Synthesis:
4-[1,2,3]TRIAZOL-1-YL-BENZALDEHYDE is utilized as a building block in organic synthesis for its reactivity, allowing chemists to create a wide range of organic compounds with diverse applications.
Used in Dye Production:
4-[1,2,3]TRIAZOL-1-YL-BENZALDEHYDE is used as a reagent in the production of dyes, where its chemical properties contribute to the creation of colorants for various industries, including textiles and printing.
Used in Polymer Industry:
4-[1,2,3]TRIAZOL-1-YL-BENZALDEHYDE is also employed in the synthesis of polymers, where its incorporation can influence the polymer's properties, such as stability, reactivity, or specific functional groups, which can be tailored for particular applications.
Used in Specialty Chemicals:
4-[1,2,3]TRIAZOL-1-YL-BENZALDEHYDE finds application in the production of specialty chemicals, where its unique structure and reactivity are harnessed to create chemicals with specific functions or properties for niche markets.

InChI:InChI=1/C9H7N3O/c13-7-8-1-3-9(4-2-8)12-6-5-10-11-12/h1-7H

Upstream product

• 288-36-8 1,2,3-triazole 
• 459-57-4 4-fluorobenzaldehyde 
• 87199-17-5 4-formylphenylboronic acid, 
• 75-20-7 calcium carbide 
• 471-25-0 Propiolic acid 
• 555-16-8 4-nitrobenzaldehdye 

Downstream Products

• 1207549-73-2 C₂₀H₂₀BrN₅O₄ 
• 1333472-83-5 2-(4-(1H-1,2,3-triazol-1-yl)phenyl)-2-methoxyacetic acid 
• 179056-48-5 Cycloheptyl-(4-[1,2,3]triazol-1-yl-benzyl)-amine 

Relevant academic research and scientific papers

Cu(I)-promoted one-pot click-SNAr reaction of nitrobenzaldehydes

A series of 1,4-disubstituted 1,2,3-triazoles containing formyl was synthesized from a variety of readily available nitrobenzaldehydes and alkynes via a convenient one-pot, click-SNAr reaction with moderate to excellent yields. The reactions we

HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS

ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Facile one-pot synthesis of monosubstituted 1-aryl-1h-1,2,3-triazoles from arylboronic acids and prop-2-ynoic acid (=propiolic acid) or calcium acetylide (=calcium carbide) as acetylene source

The synthesis of monosubstituted 1-aryl-1H-1,2,3-triazoles was achieved in a one-pot reaction from arylboronic acids and prop-2-ynoic acid or calcium acetylide (=calcium carbide), respectively, as a source of acetylene, with yields ranging from moderate to excellent (Scheme 1, Table 2). The reaction conditions were successfully applied to arylboronic acids, including analogs with various functionalities. Unexpectedly, the 1,2,3-triazole moiety promoted a regioselective hydrodebromination (Scheme 2). Copyright

N-AROYLAMINO ACID AMIDES AS ENDOTHELIN INHIBITORS

The present invention relates to the compounds of formula (I) STR1 wherein R is carboxy, esterified carboxy, carbamoyl, N-(alkyl or aryl)-carbamoyl, cyano, 5-tetrazolyl or CONH--SO 2--R 4 ; R. sub.1 is hydrogen, lower alkyl, aryl-lower alkyl or cycloalkyl-lower alkyl; R 2 is hydrogen or lower alkyl, or R 1 and R 2 represent lower alkylene to form together with the carbon and nitrogen atoms to which they are attached an azacycloalkane ring; R 3 is heterocyclic or carbocyclic (aryl or biaryl)-lower alkyl; Y is lower alkylidenyl, 3-to 10-membered cycloalkylidenyl which may be substituted by oxo, alkylenedioxy, hydroxy, acyloxy, lower alkoxy; or Y is 5-to 10-membered cycloalkylidenyl fused to a saturated or unsaturated carbocyclic 5-or 6-membered ring; or Y is 5-to 8-membered oxacycloalkylidenyl, 5-to 8-membered (thia-, oxothia-or dioxothia-) cycloalkylidenyl, or 5-to 8-membered azacycloalkylidenyl optionally N-substituted by lower alkyl or aryl-lower alkyl; R 4 represents hydrogen, lower alkyl, carbocyclic aryl, heterocyclic aryl, cycloalkyl, (carbocyclic aryl, heterocyclic aryl, cycloalkyl, hydroxy, acyloxy, or lower alkoxy)-lower alkyl, lower alkyl substituted by carboxyl, by esterified carboxyl or by amidated carboxyl; Ar represents carbocyclic or heterocyclic aryl; and pharmaceutically acceptable salts thereof; which are useful as endothelin inhibitors in mammals.

Inhibitors of acyl-coA:cholesterol O-acyltransferase. 2. Identification and structure-activity relationships of a novel series of N-alkyl-N- (heteroaryl-substituted benzyl)-N'-arylureas

A series of N-alkyl-N-(heteroaryl-substituted benzyl)-N'-arylurea and related derivatives represented by 2 and 3 have been prepared and evaluated for their ability to inhibit acyl-CoA:cholesterol O-acyltransferase in vitro and to lower plasma cholesterol levels in cholesterol-fed rats in vivo. Among these novel compounds, the type 3 series was superior. A pyrazol-3-yl group on the N-benzyl group of this trisubstituted urea (i.e. 3, Ar1 = pyrazol-3- yl) was identified as a heteroaromatic ring providing a good profile of biological activity. As a result of optimization of the combination with the N-alkyl group (R) and N-aryl group (At3), compound 3aq (FR186054) was identified as a new, orally efficacious ACAT inhibitor, which exhibited potent in vitro ACAT inhibitory activity (rabbit intestinal microsomes IC50 = 99 nM) and excellent hypocholesterolemic effects in cholesterol-fed rats, irrespective of administration mode (ED50 = 0.046 mg/kg dosed via the diet, ED50 = 0.44 mg/kg administered by gavage in PEG400 vehicle). Moreover, a toxicological study revealed compound 3aq to be nontoxic to the adrenal glands of dogs when tested at a single dose of 10 mg/kg po.

Antagonists of endothelin receptors

The present invention provides novel compounds having pharmacological properties represented by the general formula I STR1 processes for the manufacture, pharmaceutical compositions and the use of the compounds of formula I and salts thereof.